Clinical Trial Update: A Study of IBI362 9 mg in Chinese Adults With Obesity [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for IBI-362 9 mg in Chinese adults with obesity, with the study currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• IBI-362

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Obesity | Phase 3 | Status: ACTIVE_NOT_RECRUITING